Intranasal administration of guanidinylated aminoglycosides
This disclosure relates to intranasal administration of conjugates comprising guanidinylated aminoglycosides (“guanidinoglycosides”) and a polypeptide (e.g., an enzyme, antibody, or polypeptide growth factor). For example, such administration methods are useful for delivering a polypeptide to the brain and/or cerebrospinal fluid. Such methods are useful for treating a lysosomal storage disease through intranasal administration of a conjugate comprising one or more guanidinoglycosides and an enzyme useful for treating a lysosomal storage disease.
1. A method for treating a CNS or neurological disorder in a patient in need thereof, the method comprising intranasally administering to the patient a therapeutically effective amount of a conjugate comprising one or more guanidinoglycosides and a biologic, wherein the biologic is useful for treating the CNS or neurological disorder of the patient.
2. The method of claim 1 , wherein the guanidinoglycoside is covalently bound to the biologic, wherein the covalent bond is direct or optionally through a linker.
3. The method of claim 2 , wherein the linker comprises one or more of a hydrocarbon moiety, a polyethylene glycol (PEG) moiety, an oligoamide moiety, an oligoester, and functionalized and/or chemically and enzymatically cleavable moieties.
4. The method of claim 1 , wherein the biologic is a monoclonal antibody or a purified immunoglobulin fraction.
5. The method of claim 1 , wherein the biologic is selected from the group consisting of 3F8, 8H9, aducanumab, bapineuzumab, briakinumab, crenezumab, gantenerumab, ibalizumab, nimotuzumab, ozanezumab, pateclizumab, ponezumab, priliximab, pritumumab, PRO 140, ustekinumab, zalutumumab, gemtuzumab, alemtuzumab, rituximab, trastuzumab, nimtuzumab, cetuximab, bevacizumab, brentuximab vedotin, denusumab, gentuzumab, ibrutumomab tiuxetan, ipilimumab, ofatumumab, panitumumab, and tositumomab.
6. The method of claim 1 , wherein the biologic is selected from the group consisting of aducanumab, bapineuzumab, crenezumab, gantenerumab, and ponezumab.
7. The method of claim 1 , wherein the CNS or neurological disorder is selected from the group consisting of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Friedreich's ataxia, Huntington's disease, Lewy body disease, cerebrovascular disorders, frontotemporal dementia, personality disorders, cognition disorders, motor dysfunction, eating disorders, sleep disorders, affective disorders, anxiety disorders, schizophrenia, brain tumors, ataxia, bovine spongiform encephalopathy, West Nile virus encephalitis, Neuro-AIDS, brain injury, spinal cord injury, and multiple sclerosis.
8. The method of claim 1 , wherein the CNS or neurological disorder is Alzheimer's disease.
9. The method of claim 1 , wherein the CNS or neurological disorder is Parkinson's disease.
10. The method of claim 1 , wherein the guanidinoglycoside comprises an aminoglycoside antibiotic.
11. The method of claim 1 , wherein the guanidinoglycoside is selected from the group consisting of guanidino-amikacin, guanidino-gentamicin, guanidino-kanamycin, guanidino-neomycin, guanidino-netilmicin, guanidino-streptomycin, guanidino-paromomycin, guanidino-dibekacin, guanidino-arbekacin, guanidino-isepamicin, guanidino-sisomicin, guanidino-ribostamycin, and guanidino-tobramycin.
12. The method of claim 1 , wherein the biologic has a molecular weight of greater than 27,500 Daltons.
13. A method for increasing the cellular uptake of a biologic useful for treating a CNS or neurological disorder in a patient, the method comprising:
a) coupling the biologic to one or more guanidinoglycosides to form a conjugate; and
b) administering a therapeutically effective amount of the conjugate to the brain of the patient via intranasal administration.
14. The method of claim 13 , wherein the guanidinoglycoside is covalently bound to the biologic, wherein the covalent bond is direct or optionally through a linker.
15. The method of claim 14 , wherein the linker comprises one or more of a hydrocarbon moiety, a polyethylene glycol (PEG) moiety, an oligoamide moiety, an oligoester, and functionalized and/or chemically and enzymatically cleavable moieties.
16. The method of claim 13 , wherein the biologic is a monoclonal antibody or a purified immunoglobulin fraction.
17. The method of claim 13 , wherein the biologic is selected from the group consisting of 3F8, 8H9, aducanumab, bapineuzumab, briakinumab, crenezumab, gantenerumab, ibalizumab, nimotuzumab, ozanezumab, pateclizumab, ponezumab, priliximab, pritumumab, PRO 140, ustekinumab, zalutumumab, gemtuzumab, alemtuzumab, rituximab, trastuzumab, nimtuzumab, cetuximab, bevacizumab, brentuximab vedotin, denusumab, gentuzumab, ibrutumomab tiuxetan, ipilimumab, ofatumumab, panitumumab, and tositumomab.
18. The method of claim 13 , wherein the CNS or neurological disorder is selected from the group consisting of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Friedreich's ataxia, Huntington's disease, Lewy body disease, cerebrovascular disorders, frontotemporal dementia, personality disorders, cognition disorders, motor dysfunction, eating disorders, sleep disorders, affective disorders, anxiety disorders, schizophrenia, brain tumors, ataxia, bovine spongiform encephalopathy, West Nile virus encephalitis, Neuro-AIDS, brain injury, spinal cord injury, and multiple sclerosis.
19. The method of claim 13 , wherein the guanidinoglycoside comprises an aminoglycoside antibiotic.
20. The method of claim 13 , wherein the guanidinoglycoside is selected from the group consisting of guanidino-amikacin, guanidino-gentamicin, guanidino-kanamycin, guanidino-neomycin, guanidino-netilmicin, guanidino-streptomycin, guanidino-paromomycin, guanidino-dibekacin, guanidino-arbekacin, guanidino-isepamicin, guanidino-sisomicin, guanidino-ribostamycin, and guanidino-tobramycin.
21. The method of claim 13 , wherein the biologic has a molecular weight of greater than 27,500 Daltons.